ArticleCell biochemistry and biophysics2026
Molecular Dynamics and Docking Reveal Enhanced Binding of HPV16 E6 Asian American Variants To non-phosphorylated DLG1.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The E6 oncoprotein from Human Papillomavirus type 16 (HPV16) interacts with PDZ-domain proteins such as DLG1, a key regulator of cell polarity and proliferation. In this study, we used an in silico approach to investigate the predicted interactions between the reference E6 protein and five variants using a domain-focused model of DLG1 in phosphorylated and non-phosphorylated states. Protein–protein docking analyses revealed variant-dependent differences in predicted binding affinity. Notably, the E-C188/G350 and AAa variants showed stronger predicted binding to the non-phosphorylated form of DLG1. In contrast, all variants exhibited reduced predicted affinity for the phosphorylated form, while the reference E6 displayed comparatively higher predicted binding. These observations suggest a preferential predicted interaction of E6 variants with the cytoplasmic, non-phosphorylated pool of DLG1, whereas the reference E6 may preferentially interact with phosphorylated DLG1. Overall, our findings provide predictive structural insights into the differential behavior of HPV16 E6 variants in their interaction with DLG1 and establish a framework for future experimental validation.
Indexed as
Identifiers
41546816What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.